Evidence map›Paper›PMID 27268204›Full record

ArticleLeukemia & lymphoma2017

Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.

Hong Luo, Jennifer A Schmidt, Yi-Shan Lee, Eugene M Oltz, Jacqueline E Payton

Abstract read
In one paragraph

Article in Leukemia & lymphoma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Emerging Gene Therapies for Genetic Hearing Loss.Journal of the Association for Research in Otolaryngology : JARO · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hong Luoa Department of Pathology and Immunology , Washington University School of Medicine , St. Louis , MO , USA.
Jennifer A Schmidta Department of Pathology and Immunology , Washington University School of Medicine , St. Louis , MO , USA.
Yi-Shan Leea Department of Pathology and Immunology , Washington University School of Medicine , St. Louis , MO , USA.
Eugene M Oltza Department of Pathology and Immunology , Washington University School of Medicine , St. Louis , MO , USA.
Jacqueline E Paytona Department of Pathology and Immunology , Washington University School of Medicine , St. Louis , MO , USA.
Washington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICSR01CA156690 · NCI · WASHINGTON UNIVERSITY · PI OLTZ, EUGENE M, PAYTON, JACQUELINE E. · 2010 to 2014
$3.1M
SEQUENCE-SPECIFIC CHROMATIN MODIFIERS; NOVEL PROTEIN THERAPEUTICS FOR B CELL LYMPHOMAR01CA188286 · NCI · WASHINGTON UNIVERSITY · PI OLTZ, EUGENE M, PAYTON, JACQUELINE E. · 2015 to 2019
$1.7M
NCATS NIH HHS UL1 TR000448NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA156690NCI NIH HHS R01 CA188286
6 · The paper itself

Abstract

Alterations to the epigenetic landscape of diffuse large B-cell lymphoma (DLBCL) play a fundamental role in deregulating genes involved in normal lymphocyte differentiation. To determine whether targeted epigenetic therapy could reverse these pathogenic chromatin changes and suppress the expression of a lymphoma oncogene, we focused on BCL6, a transcriptional repressor whose aberrant expression is tightly linked to DLBCL proliferation and survival. We fused zinc-finger (ZF) domains specific for regulatory regions in the BCL6 locus to a repressive epigenetic modifier, the Kruppel-associated box (KRAB) repressor domain. Distinct ZF-KRAB fusions repressed the local chromatin landscape, suppressed BCL6 expression, significantly impaired DLBCL growth, and caused widespread cell death in a BCL6-dependent manner. Importantly, expression of ectopic BCL6 protein rescued ZF-KRAB-induced cell death, demonstrating the modifiers' specificity. We show that sequence-specific epigenetic modifiers can alter oncogene expression and induce apoptosis in cancer cells, underscoring their potential for future development as targeted epigenetic protein therapies.

Indexed as

Epigenetic RepressionGene Expression Regulation, NeoplasticOncogenesApoptosisBinding SitesEctopic Gene ExpressionGene TargetingHistonesHumansLymphoma, Large B-Cell, DiffuseProtein BindingProto-Oncogene Proteins c-bcl-6Repressor ProteinsZinc FingersBCL6 protein, humanHistonesProto-Oncogene Proteins c-bcl-6Repressor ProteinsChemotherapeutic approacheslymphoma and Hodgkin diseasetranscription factor changes

Identifiers

PMID27268204
PMCPMC5206989
OpenAlexW2412057094

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.